Vertex Pharmaceuticals Stock EBITDA
| VRTX Stock | USD 468.13 3.57 0.77% |
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 4.6 B | 4.8 B |
Vertex | EBITDA |
Vertex Pharmaceuticals Company EBITDA Analysis
Vertex Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Vertex Pharmaceuticals EBITDA | 4.61 B |
Most of Vertex Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vertex EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Vertex Stock properly, considering its historical fundamentals such as EBITDA. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Vertex Ebitda
Ebitda |
|
According to the company disclosure, Vertex Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 4.61 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 18.13% lower than that of the firm.
Vertex EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Vertex Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Vertex Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.| Shares | Wellington Management Company Llp | 2024-06-30 | 4.1 M | Amundi | 2024-06-30 | 3.5 M | Norges Bank | 2024-06-30 | 3.4 M | Loomis, Sayles & Company Lp | 2024-06-30 | 3.1 M | Massachusetts Financial Services Company | 2024-09-30 | 2.9 M | Bank Of America Corp | 2024-06-30 | 2.6 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.4 M | Legal & General Group Plc | 2024-06-30 | 2.4 M | Hhg Plc | 2024-06-30 | 2.4 M | Capital World Investors | 2024-09-30 | 26.8 M | Vanguard Group Inc | 2024-09-30 | 23.2 M |
Vertex Fundamentals
| Return On Equity | -0.0298 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 114.82 B | ||||
| Shares Outstanding | 257.53 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 96.10 % | ||||
| Number Of Shares Shorted | 4.11 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 7.65 X | ||||
| Price To Sales | 11.35 X | ||||
| Revenue | 9.87 B | ||||
| Gross Profit | 5.32 B | ||||
| EBITDA | 4.61 B | ||||
| Net Income | 3.62 B | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 808.4 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 60.65 X | ||||
| Cash Flow From Operations | 3.54 B | ||||
| Short Ratio | 3.38 X | ||||
| Earnings Per Share | (1.92) X | ||||
| Price To Earnings To Growth | 1.22 X | ||||
| Target Price | 516.57 | ||||
| Number Of Employees | 5.4 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 120.56 B | ||||
| Total Asset | 22.73 B | ||||
| Retained Earnings | 10.14 B | ||||
| Working Capital | 10.6 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
| Net Asset | 22.73 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.